The first announced clinical trial for CRISPR therapy in DMD (CRD‐TMH‐001, NCT05514249) employed a CRISPRa strategy, which utilizes an endonuclease‐deficient Cas9 variant (dCas9) fused to the effector domain VP64 to upregulate dystrophin expression following sgRNA targeting of the gene's promoter.176. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.